Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial
This trial of dual ICIs in molecularly selected mCRPC met its primary endpoint, showing DCR > 6 in 38% of patients. Dual ICIs exhibited modest responses in the hTMB, BRCAm, and CDK12i subgroups, but demonstrated exceptional efficacy in dMMR.
Authors
- Jolique van Ipenburg
- Iris S. H. Kloots (ORCID: https://orcid.org/0000-0001-9181-1359)
- Gosse J. Adema (ORCID: https://orcid.org/0000-0002-6750-1665)
- Harm Westdorp (ORCID: https://orcid.org/0000-0002-3336-4164)
- Thamara E. Osinga
- R J Smeenk
- Marjolijn J. L. Ligtenberg (ORCID: https://orcid.org/0000-0003-1290-1474)
- Martijn H. den Brok (ORCID: https://orcid.org/0000-0002-2368-0411)
- M. Coskuntürk
- Leonie I. Kroeze (ORCID: https://orcid.org/0000-0002-2666-1742)
- Niven Mehra (ORCID: https://orcid.org/0000-0002-4794-1831)
- Winald R. Gerritsen (ORCID: https://orcid.org/0000-0003-1110-9119)
- P.H.J. Slootbeek
- H. Bloemendal
- Sandra van Wilpe (ORCID: https://orcid.org/0000-0002-0164-7549)
- James Nagarajah (ORCID: https://orcid.org/0000-0002-3555-0809)
- J.A. Schalken
- Maïté Franken
Institutions
- Radboud University Nijmegen (NL)
- University Medical Center (US)
- Radboud University Medical Center (NL)
- Centre For Human Genetics (IN)
- Center for Human Genetics (US)
- Institute of Human Genetics (PL)
Publication Details
- Journal
- Annals of Oncology
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1016/j.annonc.2024.09.004
- Citations
- 32
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 13.41
Funders
- Bristol-Myers Squibb